Bicycle Therapeutics Announces Presentations at the 2017 American Association for Cancer Research Annual Meeting

Data to highlight the development of lead molecule BT1718, a Bicycle Drug Conjugate® targeting MT1-MMP

CAMBRIDGE, United Kingdom & CAMBRIDGE, Mass.--()--Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, announced today that the company will present preclinical data supporting the ongoing development of its lead molecule, BT1718. This program is the first example of its Bicycle Drug Conjugate® technology, which allows toxic payloads to be targeted to tumor types of high unmet medical need. BT1718 targets Type 1 Matrix Metalloproteinase (MT1-MTP), which is highly expressed in many solid tumors, including triple negative breast cancer and non-small cell lung cancer. The data will be presented in three poster presentations at the Annual Meeting of the American Association for Cancer Research (AACR), being held in Washington, DC from April 1 through April 5, 2017.

Details for the poster presentations at the 2017 AACR Annual Meeting are as follows:

Title: Development of BT1718, a novel Bicycle Drug Conjugate for the treatment of lung cancer
Session Title: Novel Molecular Targets 1
Abstract #: 1167/12
Date & Time: April 3, 2017, 8:00 a.m. – 12:00 p.m. EST

Title: Bicyclic peptides for PET imaging of MT1-MMP expressing tumors
Session Title: Clinical Laboratory and Imagine Correlates
Abstract #: 3719/4
Date & Time: April 4, 2017, 8:00 a.m. – 12:00 p.m. EST

Title: BT1718, a novel bicyclic peptide-maytansinoid conjugate targeting MT1-MMP for the treatment of solid tumors: Design of bicyclic peptide and linker selection
Session Title: Novel Drug Delivery Technology
Abstract #: 5144 / 16
Date & Time: April 5, 2017, 8:00 a.m. – 12:00 p.m. EST

About Bicycle Therapeutics
Bicycle Therapeutics is developing a new class of medicines to treat oncology and other debilitating diseases based on its proprietary bicyclic peptide (Bicycle®) product platform. Bicycles exhibit an affinity and exquisite target specificity usually associated with antibodies, while a low molecular weight delivers rapid and deep tissue penetration enabling more efficient tumor targeting. Their peptidic nature provides a “tuneable” pharmacokinetic half-life and a renal route of clearance, avoiding the liver and gastrointestinal tract toxicities often seen with other drug modalities. Bicycle Therapeutics is rapidly advancing towards the clinic with its lead molecule, BT1718, and is collaborating in oncology and other areas to realize the full potential of the technology. Bicycle Therapeutics’ unique intellectual property is based on the work initiated at the MRC Laboratory of Molecular Biology in Cambridge, U.K., by the scientific founders of the company, Sir Gregory Winter and Professor Christian Heinis. Bicycle Therapeutics is headquartered in Cambridge, U.K., with a U.S. subsidiary in Cambridge, Massachusetts. For more information, visit www.bicycletherapeutics.com.

Contacts

Ten Bridge Communications (U.S.)
Sarah Sutton, +1-857-242-1619
Sarah@tenbridgecommunications.com
or
Consilium Strategic Communications (EU)
Mary-Jane Elliott / Chris Gardner / Ivar Milligan, +44 20 3709 5700
Bicycle@consilium-comms.com

Release Summary

Bicycle Therapeutics announced today that it will present preclinical data supporting the ongoing development of its lead molecule, BT1718 at AACR 2017 from April 1 through April 5, 0217.

Contacts

Ten Bridge Communications (U.S.)
Sarah Sutton, +1-857-242-1619
Sarah@tenbridgecommunications.com
or
Consilium Strategic Communications (EU)
Mary-Jane Elliott / Chris Gardner / Ivar Milligan, +44 20 3709 5700
Bicycle@consilium-comms.com